• Products
  • Suppliers
  • Sourcing Requests
  • capsule
  • Paracetamol
  • Dexamethasone
  • semaglutide
  • peptides
  • Metformin
  • Ritonavir
  • liraglutide
  • Yaan Times Biotech Co., Ltd
  • Changsha Staherb Natural Ingredients Co., Ltd.
  • PURELIFE BIOTECH CO.,LTD.
  • Biocompounds Pharmaceutical Inc.
  • Xi'an Kaixiang Photoelectric Technology Co., Ltd
  • Apollo Healthcare Resources (Singapore)
  • Shanghai UFU Laboratory Equipment Co.,Itd
  • GN Chemicals CO,Ltd.
Post Sourcing Request Exhibition
  • FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
    December 03, 2018
    Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is
  • FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
    December 03, 2018
  • Allergan, Editas Medicine to Jointly Develop EDIT-101 americanpharmaceuticalreview
    August 08, 2018

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service